{"filings":[{"id":2051364,"accession_number":"0001193125-26-332736","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2026-08-04T20:02:18+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syndax Q2 2026 revenue $72.8M; Revuforj net revenue $54.7M (+91% YoY); Niktimvo $60.3M (+67%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $72.8M (Revuforj $54.7M, Niktimvo collaboration $18.1M); H1 2026 net loss $49.4M vs $71.8M prior year.","Cash $575.1M; expects profitability; full-year 2026 R&D+SG&A ~$400M excl. $50M stock comp.","Pipeline expanded: SNDX-4321 (allosteric EGFR inhibitor for NSCLC) IND by end 2026; SNDX-62122 (menin inhibitor for MF) IND in 2027.","Topline data expected in 4Q26 from Phase 2 trials of axatilimab in IPF and frontline cGVHD.","Revuforj prescriptions ~1,500 in Q2 (+121% YoY); average treatment duration increasing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1619796,"accession_number":"0001193125-26-302608","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2026-07-14T12:30:27+00:00","items":["8.01","9.01"],"status":"ready","headline":"Syndax unveils SNDX-4321 (allosteric EGFRi) and SNDX-62122 (menin inhibitor) at R&D event","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SNDX-4321: novel mutant-selective allosteric EGFR inhibitor for NSCLC; IND expected by end of 2026, Phase 1 in 2027.","SNDX-62122: first next-gen menin inhibitor from internal library; IND and Phase 1 in MF expected in 2027.","Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26.","Revumenib Phase 1/2 trial in MF expected to initiate in 4Q26 with initial data in H2 2027.","Company highlights late-stage revumenib and axatilimab programs in acute leukemia and chronic GVHD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":974917,"accession_number":"0001193125-26-266027","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2026-06-10T21:04:43+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Syndax issues $250M of 2.25% convertible notes due 2031, net proceeds ~$243M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $250M aggregate principal amount of 2.25% Convertible Senior Notes due 2031 in private placement.","Net proceeds of approximately $243M after placement agent fees and expenses.","Proceeds to be used for general corporate purposes including R&D, commercialization, and business development.","Initial maximum conversion of 13,631,400 shares of common stock (conversion rate 54.5256 shares per $1,000).","Notes and conversion shares unregistered; issued under Section 4(a)(2) exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":973089,"accession_number":"0001193125-26-265852","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2026-06-10T20:15:16+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Syndax shareholders approve 2026 equity plans; 7.2M new shares reserved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved 2026 Equity Incentive Plan authorizing 7,200,000 new shares plus returning shares from prior plan.","Stockholders also approved 2026 Employee Stock Purchase Plan as successor to 2015 ESPP; no rollover of prior shares.","Proposal 4 (2026 Plan) passed with 33,333,263 for vs. 25,392,051 against; Proposal 5 (ESPP) passed with 58,661,941 for.","All director nominees elected and advisory vote on executive compensation passed; ratification of auditor approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":843036,"accession_number":"0001193125-26-256458","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2026-06-04T11:16:36+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Syndax raises $250M via 2.25% convertible notes due 2031; conversion price at 35% premium","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$250M aggregate principal, 2.25% interest, semiannual payments starting Dec 15, 2026, maturing June 15, 2031.","Net proceeds ~$243M after fees; used for general corporate purposes including R&D, commercialization, and BD.","Initial conversion rate 40.3894 shares per $1,000 principal, equivalent to ~$24.76/share (35% premium over June 3 closing).","Notes are senior unsecured; callable only after June 20, 2029 if stock price exceeds 130% of conversion price.","Conversion permitted upon certain stock price thresholds or specified corporate events; company may settle in cash, stock, or mix."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92603,"accession_number":"0001193125-26-197124","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syndax Q1 revenue up 224% to $64.9M; net loss narrows to $42.7M from $84.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revuforj net revenue $48.9M (+144% YoY, +11% QoQ); total prescriptions up ~160% YoY.","Niktimvo net revenue $55.1M; Syndax collaboration revenue $15.9M (50% of profit share).","Net loss $0.48/share vs $0.98/share prior year; cash and investments $352.1M.","FY2026 opex guidance ~$400M (excl. $50M stock comp); expects to reach profitability.","Topline data from Phase 2 axatilimab trials in IPF and frontline chronic GVHD expected Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":64864000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103552,"accession_number":"0001193125-26-076522","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syndax Q4 Revuforj $44.2M (+38% QoQ); Niktimvo $56M; net loss $68M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $68.7M in Q4 and $172.4M in FY2025, driven by Revuforj and Niktimvo launches.","Revuforj net revenue $44.2M in Q4 (+38% vs Q3) and $124.8M in FY2025; ~1,150 prescriptions in Q4.","Niktimvo net revenue $56M in Q4 (+22% vs Q3) and $151.6M in FY2025; Syndax collaboration revenue $42.4M FY.","Net loss $68M (0.78/share) in Q4 and $285.4M ($3.29/share) for FY2025; cash $394.1M at year-end.","FY2026 opex guidance ~$400M ex-stock comp; expects profitability from cash, revenue, and interest income."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":172352000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103551,"accession_number":"0001193125-26-010486","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Syndax reports preliminary 2025 Revuforj $125M, Niktimvo $152M net rev, cash $394M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revuforj preliminary net revenue $44M (Q4) and $125M (FY), up 38% QoQ.","Niktimvo preliminary net revenue $56M (Q4) and $152M (FY); Syndax's 50% profit share expected ~25-30% of net rev.","Cash, equivalents and marketable securities ~$394M at year-end 2025 (unaudited).","2026 R&D + SG&A expense guidance ~$400M (excl. $50M non-cash stock comp); company funded to profitability.","Key 2026 milestones: complete IPF trial enrollment, advance frontline Phase 3 revumenib trials, initiate MF proof-of-principle."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":172352000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119816,"accession_number":"0001193125-25-326961","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Syndax amends Bylaws to move to uncertificated shares effective Dec 18, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved Bylaw amendment on Dec 18, 2025 requiring all future share issuances to be uncertificated.","Existing physical certificates issued prior to Dec 18, 2025 remain valid until surrendered.","Amendment is administrative; no change to shareholder rights or capital structure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119815,"accession_number":"0001193125-25-262509","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syndax reports Q3 2025 revenue $45.9M, Revuforj net sales $32M; FDA approval for NPM1m AML on Oct 24","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $45.9M (Revuforj net $32.0M, +12% vs Q2; Niktimvo collab $13.9M).","Net loss $60.7M ($0.70/sh) vs $84.1M ($0.98/sh) year-ago; cash $456.1M.","Revuforj FDA-approved for R/R NPM1m AML Oct 24, 2025; added to NCCN Guidelines as cat 2A.","Full-year 2025 R&D+SG&A guidance narrowed to $380-$385M; expects to reach profitability.","Total Revuforj prescriptions ~850 in Q3 (+25% vs Q2); Niktimvo net sales reported by Incyte $45.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":103624000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119814,"accession_number":"0001193125-25-250052","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Syndax receives FDA approval for Revuforj in NPM1-mutated R/R AML, second indication in <1 year","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved Revuforj (revumenib) for R/R AML with NPM1 mutation in patients aged ≥1 year.","CR+CRh rate of 23% (15/65); median time to response 2.8 months; median duration 4.5 months.","First and only FDA-approved menin inhibitor for both NPM1-m AML and KMT2A-r acute leukemia.","Included in NCCN Guidelines (Category 2A) for R/R NPM1m AML; commercial launch ongoing via SyndAccess.","Company to host conference call on Oct 24, 2025 at 2:30 p.m. ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136369,"accession_number":"0000950170-25-101974","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syndax Q2 Revuforj revenue $28.6M (+43% QoQ); sNDA for mNPM1 AML with Priority Review","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revuforj net revenue $28.6M in Q2 2025, 43% increase over Q1 2025.","Niktimvo net revenue $36.2M (Incyte-reported); Syndax collaboration revenue $9.4M.","sNDA for Revuforj in R/R mNPM1 AML granted Priority Review; PDUFA Oct 25, 2025.","Cash, cash equivalents and investments $517.9M; expect funding to profitability.","Net loss $71.8M ($0.83/sh) vs $68.1M ($0.80/sh) year ago."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":57753000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153510,"accession_number":"0000950170-25-090205","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director William Meury resigns from Syndax board to become Incyte CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William Meury resigned from Syndax board effective June 24, 2025.","Meury accepted roles of President, CEO, and board member at Incyte Corporation.","Incyte is Syndax's collaboration partner for Niktimvo (axatilimab-csfr).","Resignation not due to any disagreement with Syndax's operations or policies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153509,"accession_number":"0000950170-25-073555","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"Syndax names Dr. Nicholas Botwood Head of R&D and CMO, replacing Neil Gallagher","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Nicholas Botwood appointed Head of R&D and CMO, effective May 12, 2025; succeeds Dr. Neil Gallagher who is departing.","Botwood most recently SVP, Head of Worldwide Medical Oncology at BMS; brings 25+ years oncology development experience.","Employment terms: base salary $540K, annual target bonus 45%, stock option for 215K shares, PRSU of 23,400 units.","Gallagher will remain for interim transition period; thanked for contributions including two product approvals.","Annual meeting results: all director nominees elected, say-on-pay approved (62.5M for), auditor ratified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153508,"accession_number":"0000950170-25-063514","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Syndax Q1 Revuforj rev $20M, Niktimvo rev $13.6M; sNDA for mNPM1 AML","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revuforj net revenue $20.0M in first full quarter; Niktimvo net revenue $13.6M (Incyte reported) in first partial quarter.","Submitted sNDA seeking Priority Review for revumenib in R/R mNPM1 AML under FDA RTOR program.","Initiated EVOLVE-2 pivotal frontline trial of revumenib + venetoclax/azacitidine in mNPM1 and KMT2Ar AML.","Net loss $84.8M ($0.98 per share) vs $72.4M ($0.85 per share) year ago; cash $602.1M.","Full-year 2025 R&D guidance $260-280M, total R&D+SG&A $415-435M; expects to reach profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":20042000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172244,"accession_number":"0000950170-25-030392","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Syndax Q4 Revuforj revenue $7.7M; net loss $94.2M; cash $692.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 Revuforj net product revenue $7.7M in first five weeks of U.S. launch.","Net loss $94.2M ($1.10/share) for Q4 2024 vs $72.5M ($1.00) in Q4 2023; full year net loss $318.8M ($3.72).","Cash, equivalents and investments $692.4M; expects current resources to fund to profitability.","Launched Niktimvo in Jan 2025 with Incyte; $350M royalty funding from Royalty Pharma on Niktimvo sales.","sNDA for revumenib in R/R mNPM1 AML expected Q2 2025 based on positive AUGMENT-101 data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189234,"accession_number":"0000950170-24-139121","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Syndax eliminates Chief Medical Officer role; Dr. Catherine Madigan departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CMO Catherine Madigan, M.D. ceased employment effective December 20, 2024, after position eliminated.","Severance compensation consistent with service agreement terms (Exhibits 10.24, 10.25 to 2023 10-K).","No replacement appointed; company restructures clinical leadership without a CMO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189233,"accession_number":"0000950170-24-127708","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Syndax receives FDA approval for Revuforj as first menin inhibitor for KMT2A-translocated acute leukemia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved Revuforj for R/R acute leukemia with KMT2A translocation in patients aged 1+ years.","Efficacy: CR+CRh rate 21% (22/104), median duration 6.4 months, median time to remission 1.9 months.","Safety: common AEs include hemorrhage, febrile neutropenia, differentiation syndrome; 12% discontinued.","Commercial launch of 110/160 mg tablets expected Nov 2024; 25 mg tablets in early 2025.","SyndAccess patient support program launched; oral solution available via expanded access for patients <40 kg."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189232,"accession_number":"0000950170-24-124545","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Syndax reports positive pivotal Phase 2 results for revumenib in R/R mNPM1 AML; CR/CRh 23%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: CR/CRh rate 23% (15/64; 95% CI 14%–36%; p=0.0014) in efficacy-evaluable adult patients.","ORR 47% (30/64); 75% had prior venetoclax; 36% received ≥3 prior lines of therapy.","Safety profile consistent; 5% discontinued due to TRAEs. Grade ≥3 TRAEs: QTc prolongation 21%, anemia 14%, febrile neutropenia 13%, DS 13%, platelet count decreased 11%.","sNDA filing for R/R mNPM1 AML expected in 1H25; FDA decision on KMT2Ar acute leukemias expected in 4Q24."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189231,"accession_number":"0000950170-24-121437","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syndax Q3 net loss $84.1M; revumenib PDUFA Dec 26; Niktimvo approved; $350M royalty funding","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $84.1M ($0.98/share) vs $51.1M ($0.73) in Q3 2023; R&D $71.0M, SG&A $31.1M.","Revumenib NDA under FDA RTOR with PDUFA Dec 26, 2024; topline mNPM1 AML data expected Q4 2024, potential sNDA 1H25.","Niktimvo (axatilimab) approved by FDA for chronic GVHD after ≥2 prior lines; launch early Q1 2025.","$350M royalty funding agreement with Royalty Pharma (13.8% royalty on U.S. Niktimvo sales) expected to fund to profitability.","Full-year 2024 guidance: R&D $245-250M, total op. exp. $365-370M; cash $399.6M as of Sep 30."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":16000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189230,"accession_number":"0000950170-24-120673","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Syndax sells 13.8% royalty on Niktimvo (axatilimab) to Royalty Pharma for $350M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Royalty Pharma acquires right to 13.8% of net sales of Niktimvo (axatilimab) in US and territories.","Upfront payment of $350M; aggregate payments to Royalty Pharma capped at $822.5M.","Royalty rate subject to adjustments based on future aggregate net sales.","Syndax retains repurchase right upon change of control; events of default trigger mandatory repurchase at cap."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205727,"accession_number":"0000950170-24-089235","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syndax Q2 net loss $68.1M, revumenib PDUFA extended to Dec 26, 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $68.1M ($0.80/sh) vs $44.6M ($0.64/sh) in Q2 2023; cash $454.6M as of June 30.","R&D expenses $48.7M, SG&A $29.1M; FY2024 opex guidance $355-375M with sufficient capital through 2026.","Revumenib NDA for R/R KMT2Ar leukemia PDUFA extended to Dec 26, 2024; AUGMENT-101 mNPM1 AML data expected 4Q24.","Axatilimab BLA for chronic GVHD under Priority Review with PDUFA date Aug 28, 2024.","Appointed Dr. Aleksandra Rizo to Board of Directors in May 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":3500000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222668,"accession_number":"0000950170-24-060462","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"Syndax appoints Aleksandra Rizo to Board; Morrison resigns; annual meeting votes passed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Aleksandra Rizo, M.D., Ph.D., elected to Board effective May 15, replacing Briggs Morrison who resigned.","Dr. Rizo receives $45,644 annual cash for Board service, $8,558 for Science & Technology Committee, plus initial option for 35,000 shares vesting monthly over three years.","Annual meeting results: all director nominees elected (Huber 61.9M for, Jarrett 39.5M for), executive compensation advisory vote passed (46.2M for, 16.3M against), auditor ratified (65.4M for).","Dr. Rizo is President/CEO of Vividion, brings hematology clinical development and regulatory experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222667,"accession_number":"0000950170-24-055052","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syndax Q1 net loss $72.4M ($0.85/shr); revumenib NDA & axatilimab BLA under Priority Review","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and investments $522M; management believes sufficient for operations through 2026.","Revumenib NDA for R/R KMT2Ar acute leukemia granted Priority Review; PDUFA date Sep 26, 2024.","Axatilimab BLA for chronic GVHD granted Priority Review; PDUFA date Aug 28, 2024.","Enrollment completed in AUGMENT-101 mNPM1 cohort; topline data expected 4Q24, potential sNDA 1H25.","Appointed Steven Closter as Chief Commercial Officer; R&D expenses rose to $56.5M from $34.1M YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242177,"accession_number":"0000950170-24-032514","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Syndax appoints Steven Closter as CCO as Steve Sabus resigns; expects two product launches in 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steve Sabus voluntarily resigned as CCO on March 15, 2024 due to personal reasons.","Steven Closter appointed CCO effective March 18; leads commercial strategy for anticipated launches of revumenib and axatilimab.","Closter received base salary $460K, 45% target bonus, option for 150K shares, PRSU of 25K units, and sign-on RSU of 9K units.","Closter brings over 30 years biopharma commercial experience, previously VP at Sunovion/Sumitomo Pharma America and Forest Labs/Allergan.","Company reaffirms on track for two first- and best-in-class product launches in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242176,"accession_number":"0000950170-24-021086","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syndax reports FY2023 net loss $209.4M; axatilimab PDUFA Aug 28, 2024; cash $600M through 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2023: $209.4M ($2.98 per share) vs $149.3M ($2.46 per share) in 2022.","Cash and investments: $600.5M as of Dec 31, 2023, expected to fund operations through 2026.","BLA for axatilimab in chronic GVHD granted Priority Review; PDUFA date Aug 28, 2024.","NDA for revumenib in R/R KMT2Ar acute leukemia submitted under RTOR; PDUFA date expected 1Q24.","Enrollment in AUGMENT-101 mNPM1 cohort to complete late 1Q/early 2Q; topline data in 4Q24."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259582,"accession_number":"0000950170-23-071749","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Syndax closes $230M public offering of common stock at $18.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 12,432,431 shares includes full exercise of underwriters' option to purchase 1,621,621 additional shares.","Gross proceeds of approximately $230M; net proceeds after underwriting discounts and expenses expected.","Post-offering shares outstanding as of Dec 19, 2023: 84,809,736.","Goldman Sachs, J.P. Morgan, TD Cowen, and Stifel acted as joint book-running managers.","Offering made under an existing effective shelf registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259581,"accession_number":"0001193125-23-296814","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2023-12-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Syndax announces $200M public offering of common stock at $18.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 10,810,810 shares at $18.50; gross proceeds ~$200M ($230M with overallotment).","Underwriters: Goldman Sachs, J.P. Morgan, Cowen and Company; deal expected to close Dec. 19, 2023.","Lock-up agreement: company, directors, officers, certain stockholders restricted for 60 days.","Offering made under existing S-3 shelf registration (File 333-254661)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259580,"accession_number":"0000950170-23-069683","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Syndax reports positive pivotal data for revumenib and axatilimab; BLAs/NDAs expected by year-end 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Axatilimab AGAVE-201 trial met primary endpoint: 74% ORR at 0.3 mg/kg every two weeks in refractory chronic GVHD; BLA submission planned by year-end 2023.","Revumenib AUGMENT-101 pivotal trial met primary endpoint: CR/CRh rate 23% in R/R KMT2Ar acute leukemia; NDA submission planned by year-end 2023.","Combination data showed 100% CRc with revumenib + venetoclax/azacitidine in newly diagnosed mNPM1 or KMT2Ar AML (BEAT AML trial).","SAVE AML trial all-oral combination achieved 78% CRc in R/R AML; AUGMENT-102 pediatric trial achieved 33% CRc with fludarabine-cytarabine.","Median OS for revumenib monotherapy in AUGMENT-101 was 8.0 months; 68% of CRc responders achieved MRD negativity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259579,"accession_number":"0000950170-23-058156","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syndax reports Q3 net loss $0.73/sh, initiates revumenib NDA in R/R KMT2Ar leukemia","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $51.1M ($0.73/sh) vs $35.4M ($0.58/sh) YoY; cash $379.3M as of Sep 30, 2023.","NDA submission initiated for revumenib in R/R KMT2Ar acute leukemia under FDA RTOR; completion expected by year-end 2023.","Final Phase 1 mNPM1 data: 36% CR/CRh (5/14); 100% of CR/CRh patients MRD-negative; responses durable >22 months.","Pivotal AUGMENT-101 met primary endpoint: 23% CR/CRh in KMT2Ar acute leukemia; median duration 6.4 months.","Full-year 2023 expense guidance reduced: R&D now $160-165M (prev $160-175M); total OpEx $225-230M (prev $225-240M)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259578,"accession_number":"0000950170-23-050922","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2023-10-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Syndax revumenib meets primary endpoint in pivotal AUGMENT-101 trial; CR/CRh 23% (p=0.0036)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met with CR/CRh 23% (13/57) in pooled KMT2Ar acute leukemia; p=0.0036.","65% overall response rate in KMT2Ar AML; 50% of transplanted patients received post-transplant revumenib.","Median duration of CR/CRh 6.4 months; 46% still in remission as of July 24, 2023.","Favorable safety: only 6% discontinued due to TRAEs; no discontinuations for DS or QTc prolongation.","Company to submit NDA for revumenib to FDA by year-end; funded into 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276842,"accession_number":"0000950170-23-037936","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syndax Q2 net loss $44.6M; axatilimab ORR up to 74% in cGVHD; two filings on track for 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Axatilimab AGAVE-201: ORR 74% at 0.3 mg/kg Q2W; all three cohorts met primary endpoint in cGVHD.","Revumenib AUGMENT-101 topline data from KMT2Ar cohorts expected Q3 2023; NDA filing by year-end.","Q2 2023 net loss $44.6M ($0.64/sh) vs $37.6M ($0.62/sh) in Q2 2022.","Cash and investments $418.3M; 69.7M shares outstanding.","FY 2023 R&D guidance $160-175M; total operating expenses $225-240M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276841,"accession_number":"0000950170-23-033937","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2023-07-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Syndax/Incyte axatilimab hits primary endpoint in cGVHD trial; 74% ORR at 0.3 mg/kg dose","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AGAVE-201 met primary endpoint: ORR 74% (0.3 mg/kg Q2W), 67% (1.0 mg/kg), 50% (3.0 mg/kg Q4W).","At 0.3 mg/kg dose, 60% of responders maintained response at 12 months; median DOR not reached.","Patients had median 4 prior therapies; 54% with ≥4 organs involved; 45% lung involvement.","Syndax and Incyte intend to file BLA with FDA by year-end 2023.","Safety consistent with CSF-1R inhibition; 38% SAEs in 0.3 mg/kg group; 6.3% discontinued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294667,"accession_number":"0000950170-23-024544","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2023-05-26T23:59:59+00:00","items":["1.02","8.01","9.01"],"status":"ready","headline":"Syndax enters new $200M at-the-market equity facility with TD Cowen, replacing prior $75M program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Prior $75M ATM facility terminated on March 26, 2023; gross proceeds of $25M raised before termination.","New $200M ATM agreement signed May 26, 2023; shares sold at market prices through TD Cowen as agent.","Compensation to TD Cowen up to 3.0% of gross sales price; indemnification provisions included.","Offering may be suspended by either party; termination upon full sale or agreement end.","Cooley LLP legal opinion on Placement Shares filed as Exhibit 5.1 to the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294666,"accession_number":"0000950170-23-022802","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2023-05-18T23:59:59+00:00","items":["3.03","5.03","5.07","9.01"],"status":"ready","headline":"Syndax shareholders approve increase in authorized shares from 110M to 210M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to certificate of incorporation increases authorized shares: 200M common stock + 10M preferred stock.","All four proposals passed at May 17, 2023 annual meeting; directors elected with majority support.","Advisory vote on executive compensation passed with 58.1M for vs 0.8M against; auditor ratified.","Increase provides flexibility for potential future equity financings or corporate actions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294665,"accession_number":"0000950170-23-018794","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Syndax Q1 net loss $41.1M; on track for two pivotal readouts and NDA/BLA filings in 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $41.1M ($0.59/sh) vs $37.2M ($0.63/sh) YoY; cash $449M as of Mar 31, 2023.","Topline data from AGAVE-201 (axatilimab in cGVHD) expected mid-2023; BLA filing by end of 2023.","Topline data from AUGMENT-101 (revumenib in KMT2Ar acute leukemia) expected Q3 2023; NDA filing by end of 2023.","Alexander Nolte resigned as VP, CAO; CFO Keith Goldan appointed as Principal Accounting Officer.","Full-year 2023 R&D expense guidance reaffirmed at $160-175M; total op ex $225-240M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315263,"accession_number":"0000950170-23-010756","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Syndax appoints Neil Gallagher as President, Head of R&D; Morrison transitions","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Neil Gallagher, M.D., Ph.D., appointed President, Head of R&D effective April 10, 2023; previously CMO at AbbVie.","Briggs Morrison resigns as President, Head of R&D effective April 15, 2023; will consult for 3 months, remains on board.","Gallagher receives $530k base salary, 45% target bonus, and inducement option for 250k shares vesting over 4 years.","Company expects to advance revumenib and axatilimab through pivotal data and regulatory filings in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315262,"accession_number":"0000950170-23-005069","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syndax Q4 2022 net loss $39.2M; revumenib topline data expected Q3 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $39.2M ($0.62 per share) for Q4 2022 vs net gain of $96.2M ($1.81) in Q4 2021.","Cash and investments $481.3M as of Dec 31, 2022; raised $162M from December stock offering.","Revumenib topline data from AUGMENT-101 KMT2Ar cohort expected Q3 2023; NDA filing by year-end 2023.","Axatilimab topline data from pivotal AGAVE-201 expected mid-2023; BLA filing by year-end 2023.","Guidance: Full year 2023 total operating expenses $225-240M, R&D $160-175M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315261,"accession_number":"0000950170-23-002172","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2023-02-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Syndax adopts 2023 Inducement Plan, reserving 1.9M shares for new-hire equity grants","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved 2023 Inducement Plan on Feb 2, 2023, under Nasdaq Rule 5635(c)(4) for inducement grants.","Plan reserves 1.9M shares of common stock for issuance to new employees as material inducement to employment.","Plan is substantially similar to 2015 Omnibus Incentive Plan but prohibits incentive stock options.","Grants require approval by a majority of Independent Directors or Independent Compensation Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333598,"accession_number":"0000950170-22-026546","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2022-12-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Syndax closes $172.5M public offering; shares outstanding ~68.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $172.5M from 7,840,909 shares at $22.00 per share.","Underwriters exercised full overallotment for 1,022,727 additional shares.","Goldman Sachs, J.P. Morgan and Cowen acted as joint book-running managers.","Shares outstanding after offering stand at 68,100,918 as of December 14, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333597,"accession_number":"0001193125-22-300218","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2022-12-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Syndax Pharmaceuticals prices $150M public offering of 6.8M shares at $22.00 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["6,818,182 shares offered at $22.00 each; underwriters have 30-day option for 1,022,727 additional shares.","Gross proceeds expected ~$150M ($172.5M if option fully exercised).","Underwriting led by Goldman Sachs, J.P. Morgan, and Cowen; closing expected December 9, 2022.","Directors, executive officers, and company subject to 60-day lock-up on share sales without consent.","Offering made under effective shelf registration statement (File No. 333-254661)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333596,"accession_number":"0000950170-22-026017","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2022-12-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Syndax appoints Steve Sabus as CCO; base $495K, option for 220K shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steve Sabus joins as Chief Commercial Officer effective December 5, 2022.","Annual base salary of $495,000 with target bonus of 40% and option grant for 220,000 shares.","Sabus previously CCO at Turning Point Therapeutics and 15-year Astellas veteran.","Role focuses on commercial strategy for potential 2024 launches of revumenib and axatilimab.","Severance includes 9-month base salary on termination w/o cause or good reason; 12-month + full vesting on change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333595,"accession_number":"0000950170-22-021838","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syndax Q3 net loss $35.4M; revumenib Phase 1 shows 30% CR/CRh rate, 9.1 mo median durability","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $35.4M ($0.58 per share) vs $20.6M ($0.40) prior year; cash $337.8M at Sep 30.","Revumenib Phase 1 CR/CRh rate 30% (18/60); median response 9.1 months; 75% of transplanted patients in remission.","Enrollment complete in pivotal AGAVE-201 trial of axatilimab in cGVHD; topline data expected mid-2023.","Lowered FY 2022 R&D expense guidance to $115-125M and total op ex to $145-155M, citing axatilimab cost sharing.","On track for revumenib NDA and axatilimab BLA filings by end of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351079,"accession_number":"0000950170-22-018819","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2022-09-23T23:59:59+00:00","items":["1.02","7.01","9.01"],"status":"ready","headline":"Syndax prepays $21.5M loan, terminates Hercules Capital credit agreement","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Prepaid $21.5M to Hercules Capital to satisfy all principal, interest, and fees under Feb 2020 loan; includes $1.0M end-of-term fee and $0.4M prepayment fee.","Hercules released all security interests on Syndax assets; loan agreement fully terminated as of September 23, 2022.","Prepayment does not alter prior guidance: current cash sufficient to fund operations into second half of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351078,"accession_number":"0000950170-22-015507","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syndax Q2 net loss $37.6M ($0.62/sh); on track for pivotal data in 1H23","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $378.9M; net loss $37.6M ($0.62/sh) vs $22.9M ($0.44/sh) year ago.","R&D expenses $29.7M (up from $16.9M); G&A $8.0M (up from $5.8M).","On track to report topline data from revumenib and axatilimab pivotal programs in 1H23.","Updated revumenib Phase 1 data expected 4Q22; axatilimab IPF trial start in 4Q22.","Appointed Keith A. Goldan as CFO in June 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368336,"accession_number":"0001564590-22-023045","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2022-06-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Syndax appoints Keith A. Goldan as CFO; base salary $450k, option for 230k shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Keith Goldan appointed CFO effective June 13, 2022; previously CFO at OptiNose.","Employment terms: $450k base salary, 40% target bonus, option for 230k shares (4-yr vest), $50k RSU sign-on.","Sharon Klahre named VP, Investor Relations and Communications, reporting to Goldan.","Goldan brings ~30 years biopharma CFO experience; co. expects multiple pivotal readouts in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368335,"accession_number":"0001564590-22-019515","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2022-05-11T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Syndax stockholders elect directors, approve say-on-pay, ratify auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three director nominees elected: Katkin 27.7M for/16.4M withheld, Morrison 25.4M/18.7M, Podlesak 23.4M/20.7M.","Advisory vote on executive compensation approved: 43.9M for, 227K against, 7.8K abstain.","Stockholders recommended annual say-on-pay frequency (43.4M for 1 year); board adopted annual vote.","Ratification of Deloitte & Touche as auditor: 49.2M for, 17K against, 759 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368334,"accession_number":"0001564590-22-018892","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Syndax Q1 2022 net loss $37.2M; cash $397.9M; clinical milestones on track for 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $37.2M ($0.63/sh) vs $27.7M ($0.54) in Q1 2021; R&D spend $30.0M vs $21.9M.","Cash, cash equivalents and short-term investments $397.9M; 59M shares and equivalents outstanding.","FY2022 guidance: R&D $130-140M, total opex $160-170M; Q2 opex $38-42M.","Revumenib: AUGMENT-101 enrollment completion expected later 2022; topline data 1H23; combination trials underway.","Axatilimab: FDA Fast Track for cGVHD; AGAVE-201 topline data 1H23; potential BLA filing 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387650,"accession_number":"0001564590-22-008030","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2022-03-01T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Syndax reports Q4 net profit of $96.2M from Incyte deal; names new CMO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net profit $96.2M ($1.81/sh) vs loss $20.4M prior Q; revenue $126.6M from Incyte collaboration.","Cash $439.9M at Dec 31; FY2022 R&D guidance $130-140M, total opex $160-170M.","Kate Madigan appointed CMO effective March 1, succeeding Michael Meyers who retires.","Pivotal trials for SNDX-5613 and axatilimab enrollment on track; topline data expected 1H2023, potential NDA/BLA filing 2023.","Three new trials of SNDX-5613 expected to initiate 1H2022."],"consensus_eps_estimate":null,"consensus_eps_actual":0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":139709000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387649,"accession_number":"0001564590-22-006493","cik":1395937,"company_name":"Syndax Pharmaceuticals Inc","ticker":"SNDX","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Fabrice Egros resigns from Syndax board; Dennis Podlesak joins Audit Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Fabrice Egros resigned from Syndax board effective Feb 23, 2022 due to expanded role at Lupin Limited.","Resignation not due to any disagreement with the company on operations, policies, or practices.","Board appointed Dennis G. Podlesak to the Audit Committee following Egros' departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1717155976.9281995,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-02-24T23:59:59+00:00|387649"}